After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?

Eli Lilly (LLY) reported strong earnings, driven by its weight loss drug portfolio, including Mounjaro and Zepbound. The company's GLP-1 drugs, administered via weekly injections, help control appetite and insulin levels, expanding to oral weight loss drugs for patients unable to take injections. This strategy boosted revenue by 39% to $24 billion in the latest quarter, with Mounjaro sales rising 65% to $10 billion and Zepbound sales increasing 49% to $5.3 billion.

The stock price has climbed 27% this year, trading at a record high of over $1,300, though it is currently trading at a premium valuation of 42x forward earnings estimates. Despite this, the weight loss drug market shows significant growth potential, with only a small percentage of potential patients currently accessing weight loss care in the U.S. Lilly's pipeline includes late-stage trials for drugs like retatrutide, which could further enhance the company's market position.

Analysts suggest that buying the stock at its current price might be justified, as there is still room for growth, and the company's solid weight loss portfolio and expanding market demand provide ample room for future gains.